Fig 1.
PRISMA flow diagram.
Table 1.
Study Characteristics.
Fig 2.
Risk of bias graph and summary.
Panel A: Risk of bias graph: review authors’ judgments about each risk of bias item presented as percentages across all included studies. Panel B: Risk of bias summary: review authors’ judgments about each risk of bias item for each included study.
Fig 3.
Network of treatment comparisons.
The size of the nodes represents the total sample size of treatments. The lines’ thickness corresponds to the number of trials that compare each other. Panel A: Network of treatment comparisons for the BMD in LS. Panel B: Network of treatment comparisons for the fracture rate. ALE: Alendronate; PLA: Placebo; ALF: Alfacalcidol; RIS: Risedronate; IBA: Ibandronate; ZOL: Zoledronate; STR: Strontium Ranelate; TER: Teriparatide; PTH: Parathyroid Hormone.
Fig 4.
Pooled SMD for the BMD in LS by Bayesian network meta-analysis and traditional meta-analysis.
ALE: Alendronate; PLA: Placebo; ALF: Alfacalcidol; RIS: Risedronate; IBA: Ibandronate; ZOL: Zoledronate; STR: Strontium Ranelate; TER: Teriparatide; PTH: Parathyroid Hormone.
Fig 5.
Ranking of treatments in terms of the BMD in LS and fracture rate.
ALE: Alendronate; PLA: Placebo; ALF: Alfacalcidol; RIS: Risedronate; IBA: Ibandronate; ZOL: Zoledronate; STR: Strontium Ranelate; TER: Teriparatide; PTH: Parathyroid Hormone.